Breast cancer+1
RecruitingStudy of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib
Study of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib
- Disease:Breast cancerHormone receptor positive HER2 negative breast cancer
- Substances:Ribociclib
Germany- Participants:18–64 years · 65+ years
- Substances:Ribociclib
- Sponsor:Institut fuer Frauengesundheit GmbH













